You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 15, 2025

Drug Price Trends for LEFLUNOMIDE


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for LEFLUNOMIDE

Average Pharmacy Cost for LEFLUNOMIDE

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
LEFLUNOMIDE 10 MG TABLET 35573-0447-30 0.31195 EACH 2025-01-22
LEFLUNOMIDE 10 MG TABLET 50268-0477-15 0.31195 EACH 2025-01-22
LEFLUNOMIDE 10 MG TABLET 59651-0348-30 0.31195 EACH 2025-01-22
LEFLUNOMIDE 10 MG TABLET 50268-0477-11 0.31195 EACH 2025-01-22
LEFLUNOMIDE 20 MG TABLET 70748-0130-06 0.30499 EACH 2025-01-22
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Best Wholesale Price for LEFLUNOMIDE

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Unit Dates Price Type
LEFLUNOMIDE 10MG TAB AvKare, LLC 42291-0420-30 30 16.98 0.56600 EACH 2023-06-15 - 2028-06-14 FSS
LEFLUNOMIDE 20MG TAB AvKare, LLC 42291-0421-30 30 11.75 0.39167 EACH 2023-06-15 - 2028-06-14 FSS
LEFLUNOMIDE 10MG TAB AvKare, LLC 60505-2502-01 30 20.90 0.69667 EACH 2023-08-07 - 2028-06-14 FSS
LEFLUNOMIDE 20MG TAB AvKare, LLC 60505-2503-01 30 18.35 0.61167 EACH 2023-08-07 - 2028-06-14 FSS
LEFLUNOMIDE 20MG TAB Sanofi Aventis U.S. LLC 00955-1737-30 30 12.56 0.41867 EACH 2023-06-01 - 2028-05-31 Big4
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Unit >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for Leflunomide

Introduction to Leflunomide

Leflunomide, commonly known by its brand name Arava, is a disease-modifying antirheumatic drug (DMARD) used primarily to treat adult moderate to severe rheumatoid arthritis and other autoimmune diseases such as psoriatic arthritis. Here is a comprehensive analysis of the market trends, drivers, and price projections for Leflunomide.

Market Size and Growth Projections

The global Leflunomide market is anticipated to experience significant growth over the coming years. Here are some key projections:

  • Global Market Size: The Leflunomide market was valued at USD 3 Billion in 2023 and is projected to reach USD 6 Billion by 2030, growing at a CAGR of 11.9% during the forecast period from 2023 to 2030[3].
  • CAGR: The market is expected to witness a compound annual growth rate (CAGR) of 7.21% from 2024 to 2031, reaching a valuation of USD 41.22 billion by 2031[4].
  • Regional Growth: The Asia Pacific region, particularly China, is forecasted to show high growth potential, driven by increasing demand and stabilizing economic conditions[1].

Market Drivers

Several factors are driving the growth of the Leflunomide market:

  • Increasing Prevalence of Autoimmune Diseases: The rising global prevalence of rheumatoid arthritis and other autoimmune diseases is a major driver. As more patients seek effective treatments, the demand for Leflunomide increases[2][4].
  • Advancements in Healthcare: Improvements in healthcare infrastructure and access to medical treatments, especially in emerging economies, are boosting the demand for Leflunomide[2][4].
  • Research and Development: Ongoing research into new applications of Leflunomide and the development of new DMARDs are accelerating market growth[2].
  • Government Support and Legislation: Supportive government legislation and increasing awareness about the benefits of Leflunomide also contribute to market expansion[2].

Market Segmentation

The Leflunomide market is segmented based on several criteria:

  • Type: The market is segmented into 99% Purity and 99.5% Purity segments, with both segments expected to grow at significant CAGRs over the forecast period[1].
  • Application: The primary applications are in the treatment of Rheumatoid Arthritis and other autoimmune diseases[1][3].
  • Distribution Channel: The drug is distributed through hospital pharmacies, retail pharmacies, and online pharmacies[2].
  • Geography: The market is classified into North America, Europe, Asia Pacific, and the rest of the world, with Asia Pacific showing high growth potential[1][3].

Key Players

The leading players in the Leflunomide market include:

  • Sanofi: Known for its brand name Arava.
  • DM Pharma
  • Changzhou Yabang Pharmaceutical

These companies are actively involved in research and development, mergers and acquisitions, and strategic consolidations to enhance their market positions[1][3][4].

Price Analysis

The cost of Leflunomide can vary based on several factors, including the pharmacy and the patient's insurance status:

  • Cost per Supply: The cost for a 20 mg oral tablet of Leflunomide is around $108 for a supply of 30 tablets, depending on the pharmacy[5].
  • Discounts and Assistance: Patients can benefit from discount cards and patient assistance programs, which can reduce the cost significantly[5].

Regional Market Outlook

  • Asia Pacific: This region is expected to show high growth potential, driven by demand from countries like China. The Leflunomide market in China is forecast to reach significant valuations by 2029, with a notable CAGR[1].
  • North America: The U.S. market is also expected to grow, albeit at a slightly lower CAGR compared to the Asia Pacific region[1].
  • Europe: European countries such as Germany, France, and the UK are significant markets, with steady growth anticipated[1][2].
  • Latin America and Middle East & Africa: These regions present both opportunities and challenges, with economic fluctuations and political instability affecting market dynamics[4].

Challenges and Restraints

Despite the positive growth outlook, the Leflunomide market faces some challenges:

  • Regulatory Hurdles: The long approval process for drugs and stringent regulations are expected to obstruct market growth[2].
  • Competition: The presence of alternative treatments and the competitive landscape of the pharmaceutical industry can also pose challenges[4].

Key Takeaways

  • The Leflunomide market is driven by the increasing prevalence of autoimmune diseases and advancements in healthcare.
  • Asia Pacific, particularly China, is a high-growth region.
  • Key players like Sanofi, DM Pharma, and Changzhou Yabang Pharmaceutical are driving market growth through R&D and strategic consolidations.
  • The market faces challenges from regulatory hurdles and competition from alternative treatments.

FAQs

  1. What is the expected CAGR of the Leflunomide market from 2024 to 2031?

    • The Leflunomide market is anticipated to witness a CAGR of 7.21% from 2024 to 2031[4].
  2. Which region shows the highest growth potential for the Leflunomide market?

    • The Asia Pacific region, particularly China, shows high growth potential[1].
  3. What are the primary applications of Leflunomide?

    • The primary applications are in the treatment of Rheumatoid Arthritis and other autoimmune diseases[1][3].
  4. Who are the leading players in the Leflunomide market?

    • The leading players include Sanofi, DM Pharma, and Changzhou Yabang Pharmaceutical[1][3][4].
  5. What are the main challenges facing the Leflunomide market?

    • The main challenges include regulatory hurdles and competition from alternative treatments[2][4].

Sources

  1. QY Research: Leflunomide - Global Market Insights and Sales Trends 2024
  2. Data Bridge Market Research: Global Leflunomide Market - Industry Trends and Forecast to 2029
  3. Verified Market Reports: Leflunomide Market Size, Share & Growth
  4. OpenPR: Leflunomide Market Size, Share and Forecast By Key Players
  5. Drugs.com: Leflunomide Prices, Coupons, Copay Cards & Patient Assistance

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.